What is Xenocor?
Founded in 2016 and headquartered in Salt Lake City, Utah, Xenocor specializes in the engineering of disposable surgical laparoscopes designed for both abdominal and thoracic procedures. By addressing the persistent clinical challenge of lens fogging during surgery, the company provides surgeons with uninterrupted, high-definition visualization. This technological edge not only enhances procedural precision but also streamlines operating room workflows by eliminating the need for traditional sterilization cycles associated with reusable equipment. The company's current market position is defined by its commitment to improving patient outcomes through superior optical clarity and operational efficiency in the surgical suite.
How much funding has Xenocor raised?
Xenocor has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2023): $10M with participation from Baranco Investments, Barvest Ventures, Patel Family Investments, and GenHenn Venture Fund I
Key Investors in Xenocor
Baranco Investments
A private investment firm focused on long-term capital appreciation within the healthcare and medical technology sectors.
Barvest Ventures
A venture capital entity specializing in early-to-growth stage medical device startups with high-impact clinical applications.
Patel Family Investments
A family office investment group that provides strategic backing to innovative companies disrupting traditional surgical methodologies.
What's next for Xenocor?
With this major enterprise-level funding, Xenocor is poised to accelerate its commercial expansion and deepen its research and development pipeline. The strategic allocation of these resources will likely focus on scaling manufacturing capabilities to meet the growing demand for disposable surgical hardware across North American healthcare systems. Furthermore, the company is expected to leverage this capital to pursue additional regulatory clearances and expand its product portfolio, potentially integrating advanced imaging features that further differentiate its offerings in the competitive medical device market. As Xenocor matures, the focus will remain on establishing its technology as the standard of care for minimally invasive interventions, ensuring long-term scalability and market penetration.
See full Xenocor company page
